Regent Peak Wealth Advisors LLC Buys 156 Shares of CVS Health Co. (NYSE:CVS)

Regent Peak Wealth Advisors LLC grew its stake in shares of CVS Health Co. (NYSE:CVS) by 3.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,162 shares of the pharmacy operator’s stock after buying an additional 156 shares during the period. Regent Peak Wealth Advisors LLC’s holdings in CVS Health were worth $329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Weik Capital Management grew its holdings in shares of CVS Health by 0.7% in the first quarter. Weik Capital Management now owns 17,600 shares of the pharmacy operator’s stock valued at $1,781,000 after purchasing an additional 120 shares in the last quarter. FCA Corp TX boosted its stake in CVS Health by 0.6% during the first quarter. FCA Corp TX now owns 20,109 shares of the pharmacy operator’s stock worth $2,035,000 after buying an additional 122 shares during the period. Arvest Trust Co. N A boosted its stake in CVS Health by 1.2% during the fourth quarter. Arvest Trust Co. N A now owns 11,157 shares of the pharmacy operator’s stock worth $1,040,000 after buying an additional 131 shares during the period. SOA Wealth Advisors LLC. boosted its stake in CVS Health by 4.9% during the fourth quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after buying an additional 133 shares during the period. Finally, Apella Capital LLC boosted its stake in CVS Health by 4.2% during the fourth quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock worth $272,000 after buying an additional 136 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE CVS traded down $5.74 during mid-day trading on Tuesday, hitting $73.82. The stock had a trading volume of 23,626,900 shares, compared to its average volume of 11,456,720. The firm’s 50 day moving average is $76.02 and its 200 day moving average is $73.70. CVS Health Co. has a twelve month low of $64.41 and a twelve month high of $83.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The stock has a market capitalization of $92.90 billion, a price-to-earnings ratio of 11.32, a PEG ratio of 1.05 and a beta of 0.52.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business had revenue of $93.81 billion during the quarter, compared to the consensus estimate of $90.58 billion. During the same period last year, the company earned $1.99 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. Equities research analysts forecast that CVS Health Co. will post 8.33 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date is Friday, April 19th. CVS Health’s payout ratio is 41.18%.

Insider Buying and Selling at CVS Health

In other news, EVP Prem S. Shah sold 29,473 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the transaction, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.25% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on CVS. SVB Leerink began coverage on shares of CVS Health in a research note on Monday, February 26th. They set an “outperform” rating and a $88.00 price objective for the company. Leerink Partnrs reissued an “outperform” rating on shares of CVS Health in a research note on Monday, February 26th. HSBC began coverage on shares of CVS Health in a research note on Friday, December 22nd. They set a “buy” rating and a $94.00 target price for the company. TD Cowen lowered their price objective on CVS Health from $102.00 to $99.00 and set an “outperform” rating on the stock in a research report on Monday, December 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a research report on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.44.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.